I ntramuscular (i.m.) gene transfer of plasmid DNA allows a relatively constant delivery of therapeutic proteins that are useful in many disease situations. [1] [2] [3] The method involves direct injection of naked DNA into skeletal muscle and expression of the plasmid-encoded gene. The gene transfer efficiency can be markedly improved when plasmid injection is combined with local electroporation. 4, 5 Some studies have shown that DNA vaccination methods based on this strategy can induce protective antitumor immunity. 6 In these cases, tumorassociated antigens (TAAs) and immunostimulatory molecules such as cytokines (e.g. interleukin (IL)-12, interferon (IFN)-g) are synthesized by the muscle cells, and perhaps also antigen-presenting cells (APCs), after gene transfer. T helper (Th) responses, cytotoxic T lymphocytes (CTLs), and antibodies can be induced, to a degree depending on the type of cytokine produced. It is also possible to bias the response towards either a Th1 or a Th2 type. 7, 8 For an effective antitumor response to be established, T lymphocytes need to be activated to become effector cells. Optimal T-cell activation requires both specific antigen recognition (signal 1) and costimulatory signals (signal 2). In the absence of signal 2, T cells fail to respond effectively and become anergic. The B7.1/B7.2-CD28/ CTLA4 pathway is the best-characterized T-cell costimulatory pathway and is crucial in T-cell activation and tolerance. Interaction of B7.1/B7.2 on APCs with CD28 on T cells delivers a strong costimulatory signal, whereas binding to CTLA-4, whose level is upregulated following T-cell activation, causes T-cell inhibition. 9 Based on this regulatory mechanism, enhancement of immune responses can be achieved by either boosting CD28 signaling or blocking CTLA-4 function. The validity of this idea has been demonstrated by several studies, with activating/ blocking antibodies or either CTLA4 or B7.1/ B7.2 fused with an immunoglobulin G (IgG) Fc portion. [10] [11] [12] The soluble B7.1/IgG 1 fusion protein, which can circulate in the bloodstream, has been shown to be functionally equivalent to the membrane-bound wild-type (WT) form in providing T-cell costimulation. 13 As a dimer joined by the Ig Fc portion, the protein is also thought to be able to crosslink CD28 on T cells, which facilitates CD28 signaling. 14 Several studies have shown that administration of this fusion protein can induce potent antitumor effects. Different ways of delivering this molecule have been described, including gene transfer using viral vectors and systemic/intratumoral injection of purified or recombinant protein. [13] [14] [15] However, the efficacy of soluble B7.1/ IgG 1 as an adjuvant in cancer immune therapy has never been studied in the context of i.m. gene transfer. In the present study, i.m. delivery of plasmid DNA encoding B7.1/IgG 1 fusion protein caused an efficient and prolonged expression of this protein without the occurrence of systemic adverse effects. Coinjection of plasmids encoding human carcinoembryonic antigen (CEA), as a model tumor antigen, and B7.1/IgG 1 induced potent antitumor immunity. Comparison of soluble versus membrane-bound WT B7.1 showed a superior antitumor effect induced by the soluble protein. We also found that B7.1/IgG 1 exerted its effects primarily as a costimulatory molecule instead of as a direct antitumor agent. Muscle histopathology revealed minimal muscle damage, suggesting that the method is safe.
Materials and methods

Construction of expression plasmids
Modified VR1255 (VICAL Inc., San Diego, CA, USA) 16, 17 was used as a vector for plasmid construction. The vector has a high expression capacity in muscle. This plasmid has a CMV enhancer/promoter and a rabbit beta-globulin transcriptional terminator.
The coding sequences of mouse B7.1 and a mouse IgG 1 Fc segment were fused by overlapping PCR 17 using two sets of primers with proper restriction sites incorporated at both ends (EcoRV and EcoRI). Primers were designed to omit the B7.1 transmembrane domain. The B7.1 coding sequence was fused in frame to IgG 1 Fc to give a final product of 1.6 kb in length. The resulting B7.1/ IgG 1 Fc fusion sequence was cloned into VR1255 vector (denoted as VR-B7.1/IgG 1 ) and confirmed by sequencing.
VR1255-based plasmids encoding full-length WT B7.1 (B1 kb insert) or human CEA (B2.4 kb insert) were also constructed (denoted as VR-wt B7.1 and VR-CEA, respectively).
Stable transfection line of LLC/CEA
Mouse Lewis lung carcinoma (LLC) was transfected with pCI-CEA neo plasmid and selected for stable transfectants using geneticin, G418, designated as LLC/CEA. 7 Cells were cultured in the selection medium (DMEM, 5% FBS, 1000 mg/ml G418). The expression of CEA on LLC/ CEA cells was analyzed by flow cytometry using anti-CEA monoclonal antibody (purified from hybridoma line B18) as the primary antibody and goat anti-mouse IgG-FITC conjugate (BD PharMingen Canada, ON, Canada) as the secondary antibody. At least 85% of the cells were confirmed to express CEA before transplantation.
Plasmid DNA preparation
All plasmids were prepared by the alkaline lysis method using the EndoFreet Plasmid Giga kit (QIAGEN, CA) according to the manufacturer's instructions. Purity and correct conformation of plasmid products were confirmed by enzyme digestion and size fractionation by electrophoresis. Plasmids were dissolved in sterile saline (0.85% NaCl) at a concentration of 2 mg/ml and stored at À801C until injection.
Mouse DNA gene transfer protocol
We previously established an optimal i.m. gene transfer protocol. 6 Briefly, 7-to 8-week-old male C57BL/6 mice (H-2 b ) (Charles River, Quebec, Canada) were anesthetized and plasmid DNA was injected in the rectus femoris muscle. For coinjection of two plasmids, 50 mg plasmid DNA (25 mg of each plasmid) in 25 ml saline was injected in each leg, that is, 100 mg plasmid per animal. Blank vector (VR 1255) was added to normalize the total amount of plasmid DNA administrated, when only one expression plasmid needed to be injected. After injection, muscles were immediately electroporated using caliper electrodes applied to the skin (coated with conductive gel) with an Electro Square Poratort (Genetronics, San Diego, CA) using the following setting: 80 V/cm, 20 millisecond pulse length for eight pulses at 1-second intervals. A complete DNA gene transfer treatment consists of five identical injections administrated at 1-week intervals.
ELISA assay for B7.1/IgG 1 B7.1/IgG 1 levels were determined by ELISA assay using anti-mouse B7.1 monoclonal antibody (PharMingen Canada, ON, Canada) as the capture antibody and polyclonal goat anti-mouse IgG 1 labeled with alkaline phosphatase (AKP) as the detector antibody (PharMingen Canada, ON, Canada). An AKP substrate kit (BIO-RAD, CA) was used for measuring AKP activity, and the optical density (OD) of the product (nitrophenol) was determined at 405 nm by an ELISA microtiter plate autoreader (TiterTek Multiscan s , Labsystem, Finland).
In vitro lymphocyte proliferation assay with CEA stimulation Six treatment groups (n ¼ 6 mice/group) were compared: (1) blank vector, (2) VR-B7.1/IgG 1 plasmid alone, (3) VR-CEA plasmid alone, (4) VR-wt B7.1 plasmid alone, (5) VR-CEA and VR-wtB7.1 plasmids coinjection, and (6) VR-CEA and VR-B7.1/IgG 1 plasmids coinjection. After completion of DNA vaccination schedule, mouse spleen and popliteal lymph node cells were pooled and single-cell suspensions were prepared from each treatment group. Cells were cultured in lymphocyte culture medium AIM V (GIBCO BRL, ON, Canada) that was supplemented with 50 mM b-mercaptoethanol. In vitro cytokine release assay with CEA stimulation Single-cell suspensions were prepared as described in the lymphocyte proliferation assay. Cells (5 Â 10 6 ) in 1 ml of culture medium containing 50 mM b-mercaptoethanol were added into each well (24-well plate). Cells were stimulated with CEA (100 mg/ml), OVA (100 mg/ml), or medium only in each group. Supernatants were collected after 4 days and IFNg and IL-4 levels were measured using the OptEIAt ELISA set for mouse IFNg and IL-4 (PharMingen, CA).
Cytotoxic T-lymphocyte (CTL) killing assay
Preparation of effector cells. Three treatment groups (n ¼ 6 mice/group) were compared: (1) blank vector, (2) VR-CEA plasmid alone, and (3) VR-CEA and VR-B7.1/ IgG 1 plasmids coinjection. Spleen and popliteal LN cells were pooled and single-cell suspensions were prepared. 4 Â 10 6 cells/well (in 1 ml) were cultured (24-well plate) in RPMI 1640 medium supplemented with 5% heat-inactivated fetal bovine serum (GIBCO BRL, ON, Canada), 15 mM HEPES (pH 7.4), 2 mM l-glutamine, 0.1 mM nonessential amino acid (GIBCO BRL, ON, Canada), 1 mM sodium pyruvate, 10 mg/ml gentamicin, and 50 mM b-mercaptoethanol. Cells were sensitized with 20 mg/ml CEA 526-533 peptide (Sheldon Biotechnology Center, Montreal, Canada) and recombinant murine IL-2, 15 U/ ml (BioSource, CA) for 5 days. Nonadherent effector cells were harvested 5 days later and viable cells were recovered by Ficoll-Paque density gradient (Histopaque s -1083; Sigma, ON, Canada). Viable cells were resuspended in RPMI medium and put on ice until CTL activity was assayed. Peptide CEA 526-533 corresponds to amino-acid position 526-533 (EAQNTTYL), and was demonstrated to be immunodominant in the mouse MHC I (H-2 b ) context, and is effective at inducing CTL-mediated killing. 18 Preparation of target cells. Syngeneic (C57BL/6) mouse T-cell lymphoma EL-4 H-2 b line (ATCC-TIB 39, ATCC, Manassas, VA) was used as a target line. EL-4 cells were cultured with 20 mg/ml CEA 526-533 peptide. EL4 cells were cultured without CEA 526-533 peptide to serve as controls. On the day of the experiment, EL4 cells were labeled with 51 Cr. After 1 hour culture at 371C, 51 Cr-labeled EL4 cells were washed and resuspended in RPMI 1640 medium for CTL assay.
CTL assay. Effector and target cells were mixed at an E:T ratio ranging from 100 to 12.5:1 in a total volume of 200 ml/well, in four replicates. For each treated group, CTL activity was assessed with and without CEA 526-533 peptide pulsing of target cells. Specific lysis (%) for each E:T ratio was calculated using mean cpm of four wells by the following formula: percentage of specific lysis ¼ [(experimental cpmÀspontaneous cpm)/(maximal cpmÀspontaneous cpm)] Â 100.
Tumor-cell challenge
This was performed as previously described. 6, 7 Briefly, 1 week after the final (fifth) DNA injection, each mouse was transplanted with 1.5 Â 10 5 CEA/LLC cells subcutaneously in the right flank (n ¼ 12 mice/group). Tumor growth was measured by a caliper in two dimensions, and the volumes were calculated using the formula (width 2 Â length)/2. Tumor volume and tumor incidence were checked once a week for 3 weeks.
Muscle histology and immunohistochemistry
At 1 week after DNA injection, muscles were removed and fixed in PLP fixative (2% paraformaldehyde containing 0.075 M lysine and 0.01 M sodium periodate solution). Adjacent tissue sections were stained with hematoxylin and eosin (H&E), or processed for immunostaining. For immunohistochemistry, sections were proteinase digested for antigen retrieval. Rabbit anti-human CEA polyclonal antibody (DAKO, Glostrup, Denmark) was used as a primary antibody. Preimmune serum was used as a negative control. As secondary antibody, biotinylated goat anti-rabbit IgG was used (Sigma, St Louis, Missouri). After antibody incubation, sections were washed and incubated with the Vectastain ABC-AP kit (Vector Laboratories, ON, Canada) and red pigmentation to demarcate regions of immunostaining was produced by treatment with Fast Red TR (Sigma). Sections were counterstained with toluidine blue.
Statistic analysis
The statistical significance of differences between selected groups was determined using Student's t-test or one-way ANOVA. All analyses were performed using INSTAT 3.05 (GraphPad Software Inc., San Diego, CA, USA). All P-values reported are two-sided, Po.05 is considered to be significant.
Results
Intramuscular delivery of the B7.1/IgG 1 plasmid produced high serum levels of protein
The plasmid VR-B7.1/IgG 1 , which encodes B7.1/IgG 1 fusion protein, was injected intramuscularly (i.m.) followed by local electroporation, either alone or in combination with CEA-encoding or blank plasmids. After completion of five treatments, serum was collected and tested by ELISA for the B7.1/IgG 1 level (Fig 1) . Notably, VR-B7.1/IgG 1 injected alone gave the highest level of expression, while coinjection with VR-CEA reduced the expression level, suggesting competition for expression between the plasmids. After five treatments, we observed serum levels of B7.1/IgG 1 of up to 1 mg/ml. To assess the persistence of expression, a single injection of VR-B7.1/IgG 1 plasmid was administrated and serum levels of B7.1/IgG 1 were monitored for 60 days. Levels were maximal at about 10 days and decreased over the next 10 days (Fig 2) . However, a relatively constant level was maintained after 20 days. This expression pattern was similar to that found by Manthorpe et al. 19 To determine whether high levels of B7.1/IgG 1 were activating lymphocytes and inducing cytokine production nonspecifically in vivo, sera from different groups were compared for IFNg and IL-4 levels by ELISA. There was no significant difference in the levels of these cytokines between either untreated, blank vector-or VR-B7.1/IgG 1 -injected mice (data not shown).
Lymphocyte response to CEA stimulation in vitroproliferation and cytokine production assays At 1 week after completion of DNA vaccination schedule, lymphocytes from mouse spleen and popliteal lymph nodes were isolated and stimulated with purified human CEA protein or OVA in culture. As shown in Figure 3 , lymphocytes of the VR-B7.1/IgG 1 and VR-CEA coinjection group had the highest proliferation, as compared to the VR-wtB7.1 and VR-CEA coinjected group, or the group receiving only VR-CEA (Po.05). Stimulation with OVA did not produce a response in any of these groups.
Supernatants were collected after 4 days in culture and assayed for IFNg and IL-4 levels by ELISA. The highest IFNg level was observed in mice that were coimmunized with B7.1/IgG 1 and CEA (Fig 4) and this was significantly higher than the other groups (Po.05). IL-4 was undetectable by ELISA assay (detection limit of 10 pg/ml). (7) VR-CEA and VR-B7.1/IgG 1 plasmids injection at separate sites (one in each leg). Five DNA injections were administrated at 1-week intervals. This immunization schedule was found to be optimal in our previous studies. 6, 7 Mice were then transplanted subcutaneously with a syngeneic LLC/ CEA stable transfectant line. Tumor growth was monitored for 21 days. When codelivered with CEA, the B7.1 molecule served as an effective adjuvant to induce a potent antitumor effect (Figs 5, 6 ). B7.1/IgG 1 was more effective than WT B7.1, and mice coimmunized with B7.1/ IgG 1 and CEA plasmids had the lowest tumor incidence (Fig 5, Po.05) . Furthermore, those that developed tumors had delayed tumor growth (Fig 6, Po.05) . Injection of B7.1/IgG 1 and CEA plasmids at two different sites (one in each leg) gave protection against tumor as strong as same site coinjection (Figs 5, 6 ). Expression of either VR-B7.1/IgG 1 or VR-wtB7.1 alone did not give any protection against tumor.
Increased cytotoxic killing of CEA 526-533 peptide-pulsed target cells (EL4)
The syngeneic mouse T-cell leukemia line, EL4, pulsed with CEA 526-533 peptide was demonstrated to be a suitable target for studying CEA-specific CTL activity. 18 The EL4 cells were used here as a target line in substitution of LLC/CEA cells, which we found to be much less effective as targets in in vitro CTL assay, most likely because of a very low level of MHC class I (H-2 b ) Figure 4 Cytokine (IFNg) release after in vitro stimulation with CEA. Cells were prepared and stimulated as described in the lymphocyte proliferation assay. Results represent the IFNg level (mean7SEM of four replicates) after 4 days in culture (5 Â 10 6 cells in 1 ml/ well), and Groups 5 and 6 both showed a significant difference in IFNg production as compared to Group 2 (Po.05). Group 6 also showed a significant difference compared to Group 5 (Po.05). The results of a representative experiment are shown, and three experiments yielded similar results. Figure 6 Tumor growth curve. Tumor volume over time in groups of mice treated as described in the legend to Figure 5 . These results represent the mean tumor volume7SEM (n ¼ 12) for all mice in each group (tumor volume ¼ 0 in some mice). Groups 5, 6, and 7 showed a significantly lower mean tumor volume compared to the other groups (Po.05). There was also a significant difference in tumor volume between Groups 6 and 5 (Po.05). Group 7 demonstrated tumor growth inhibition as efficient as with coinjection of two plasmids at the same site (Group 6) (P4.05).
expression as found by flow cytometry analysis (our unpublished data).
The lymphocytes of VR-B7.1/IgG 1 and VR-CEA plasmids-coimmunized mice showed an increased CTL activity, as compared to blank vector or CEA plasmidimmunized mice (Fig 7) .
Muscle histology and immunohistochemistry
Five treatments were compared: (1) untreated muscle, (2) injection with saline, (3) injection with blank plasmid, (4) injection with VR-CEA plasmid, and (5) coinjection with VR-CEA and VR-B7.1/IgG 1 plasmids. Injection was administered twice using our standard DNA gene transfer protocol, including electroporation. Adjacent muscle sections were stained with hemotoxylin and eosin (H&E) or processed for immunostaining. Abundant expression of CEA was shown in groups 4 and 5 by immunohistochemistry. CEA appears to be expressed in both the cytoplasm and on the cell membrane of myocytes. We found that in the VR-CEA and VR-B7.1/ IgG 1 coinjected muscles, there was often a mononuclear cell infiltration in the areas where CEA was expressed (Fig 8) . This was much less apparent in VR-CEA-injected muscles and was totally absent in other treatment groups. Notably, central displacement of nuclei was often seen in the muscle fibers expressing CEA and this did not appear to depend on mononuclear cell infiltration. Such a change was equally frequent in both the coinjected (VR-CEA and a3, a4, b3, b4) . Mononuclear cell infiltration was apparent in the areas where CEA was expressed, especially in the VR-CEA+VR-B7.1/IgG 1 -coinjected muscles (H&E, b1, b2). Central displacement of nuclei in the muscle fibers expressing CEA in both treatment groups (H&E, a1, a2 and b1, b2) suggests the occurrence of minor muscle damage. This was equally frequent in both coinjected (VR-CEA+VR-B7.1/IgG 1 ) and VR-CEA-injected groups. Both mononuclear cell infiltration and central displacement of nuclei were absent in all other groups, that is, untreated muscle, muscle injected with saline, and muscle injected with blank plasmids (not shown). No morphologic change related to muscle fiber size and structure was seen in all groups.
VR-B7.1/IgG 1 ) and VR-CEA-injected groups and was totally absent in other comparison groups. We did not see obvious morphologic changes related to muscle fiber size and structure.
Discussion
Codelivery of plasmid vectors encoding tumor antigens and adjuvant molecules is an effective strategy for the enhancement of antitumor immunity. Although both B7.1 and B7.2 can activate the CD28 pathway, B7.1 was shown to be stronger than B7.2 in inducing cell-mediated immunity, and especially at activating naı¨ve CD8 + T cells. [20] [21] [22] In some cases, ectopic expression of B7.1 on tumor cells may also promote natural killer cell-mediated cytolysis. 23, 24 The soluble form of B7.1, the B7.1/IgG 1 , is a potent costimulatory molecule that has been used either prophylactically or, in some cases, even therapeutically after tumors are established.
14 The current study demonstrates the efficacy of using this soluble protein as an adjuvant when the gene is administrated by the i.m. route. The antitumor effect induced was strong, as indicated by the significantly reduced tumor incidence and growth as compared to the control groups.
Lymphocytes isolated from immunized mice showed significantly increased proliferation and IFNg release upon in vitro stimulation with purified CEA protein. CTL killing of CEA 526-533 peptide-pulsed EL4 cells was also increased, indicating that specific immunity against CEA, a poorly immunogenic tumor antigen, was established. Expression of soluble B7.1/IgG 1 alone did not provide any protection against tumor, confirming its primary role as a costimulatory molecule rather than a direct antitumor agent. Of note, high levels of B7.1/IgG 1 did not cause any obvious abnormality in these mice. IFNg and IL-4 serum levels remained normal in treated mice and there were no signs of autoimmunity or increased morbidity in mice kept for several months after DNA vaccination.
Comparison of soluble B7.1/IgG 1 with membranebound WT B7.1 showed that the soluble protein had a superior antitumor effect. Moreover, the plasmid encoding soluble B7.1/IgG 1 did not need to be injected at the same site as the antigen plasmid to exert its effect. Thus, circulating B7.1/IgG 1 protein was sufficient to enhance immunity. This is particularly interesting, as circulating protein might also fortuitously enhance some other immune responses occurring against an immunogenic tumor.
Compared with our previously published results using an IL-12 p35/p40 biscistronic plasmid as a vaccine adjuvant, 6, 7 the antitumor effects seen with the B7.1/ IgG 1 vector are equally potent. However, following i.m. IL-12 plasmid administration, this cytokine was observed in the circulation, which is a potential drawback. Indeed, IL-12, like several other cytokines, is toxic and can give rise to many adverse effects. The administration of a B7.1/ IgG 1 plasmid eliminates this concern, since there is no evidence that this mediator is toxic, even at high serum levels (our unpublished observations). Importantly, the IL-12 plasmid was found to act only locally, when administered i.m. at the same time and at the same site as the antigen expression plasmid. Circulating IL-12 had no adjuvant effect for tumor immunity in our DNA vaccination model. In contrast, circulating B7.1/IgG 1 has strong adjuvant activity, and is likely to enhance any ongoing antitumor response, regardless of the initiating antigen or site of antigen presentation.
Several mechanisms have been proposed for the superior function of this soluble protein to its membranebound form in vivo, including prolonged presence in the circulation, a possible crosslinking effect on CD28 because of its bivalent nature and a functional role played by the IgG Fc portion. 14, 25 However, given the complexity of the B7-CD28/CTLA-4 costimulatory pathway, 9, 26, 27 it remains to be seen how soluble-form B7/IgG protein interacts with its counterparts, CD28 and CTLA-4, during T-cell activation. Enhanced T-cell activation is thought to occur primarily through CD28 stimulation. However, there is also evidence that B7/IgG may exert its activity through a pathway(s) other than CD28. In a study using B7.1, B7.2, and CTLA-4 triple knockout (TKO) mice, soluble B7/IgG was unable to prevent tumor growth in the presence of only the CD28 pathway. Use of an anti-CD28 antibody, however, induced an antitumor effect in these mice. 28 The reason for this is unclear, but studying CD28 KO mice might help to resolve the question. On the other hand, binding of B7.1/IgG to CTLA-4 did not appear to trigger a strong inhibitory signal, inasmuch as immunity was enhanced. In all the studies using soluble B7/IgG, including B7.2/IgG, downregulation of T-cell response did not occur in cells expressing CTLA-4, even though CTLA-4 has a much higher affinity than CD28 for B7. 29 It is also possible that B7/IgG may possess similar properties as anti-CTLA-4 antibodies to enhance immunity through CTLA-4 blockade. 10, 30, 31 These findings suggest benefits of using soluble B7/IgG, which may depend on multiple mechanisms, some as yet unknown.
Elevated production of IFNg in vitro in response to CEA was noted, and this Th1-type cytokine may be an important mediator in the B7.1/IgG-induced antitumor immunity. An effector role for IFNg is consistent with our previous findings, where antitumor immunity was greatly reduced in IFNg KO mice. 6 A Th2-type response is probably not a major factor in the current study, as IL-4 remained undetectable in all in vitro stimulation assays.
Given the abundant expression of IgG Fc receptors on macrophages, NK cells, and neutrophils, with either activating or inhibitory functions, 32 the IgG Fc portion may play a role in antitumor immunity in vivo. For instance, it can be hypothesized that the Fc portion of the B7.1/IgG fusion protein brings the APC (via IgG Fc receptors) in close proximity to T cells (via the B7.1 portion) and promotes an APC-T-cell interaction. In this process, both the APC and the T cell might receive activating signals. Surprisingly, however, a study by Sturmhoefel et al 14 with B7/IgG using WT Fc or nonfunctional mutant Fc (the mutation abrogating FcgRI and complement C1q binding) showed an equal antitumor effect. The cellular mechanisms involved in priming a CTL response after the injection of naked plasmid DNA have not been totally elucidated. Using expression systems controlled by cell-specific promoter, some reports have suggested a predominant role of antigen transfer from nonlymphoid cells to APCs, a process called crosspriming or crosspresentation. 33, 34 Although it is true that injected DNA may directly transfect APCs, in muscle tissue there are few resident APCs and the transfected muscle cells may serve as a primary antigen reservoir. Thus, presentation may occur after antigen transfer from myocytes to professional APCs, particularly DCs. Antigen expression levels are one of the major factors that influence crosspresentation. 35 In our case, the abundant expression of CEA in the cytoplasm and on the cell membrane (characterized by immunostaining) might facilitate this process. Interestingly, in our study, antitumor immunity was also induced by expression of WT membrane-bound B7.1. Since T cells are thought to be activated in lymph nodes, it is difficult to explain how this molecule if located only on the muscle cell surface could boost T-cell responses. We hypothesize that either shed B7 is captured by APCs or these cells are directly transfected by plasmid and produce the costimulatory protein. Ongoing experiments in our laboratory using muscle-specific promoter elements may provide an answer to this question.
Muscle histology and immunohistochemistry were studied to assess the impact of this gene transfer method. We found monocyte infiltration in the areas where CEA was expressed, and this was much more obvious in the muscles coinjected with VR-CEA and VR-B7.1/IgG 1 plasmids. However, it is unclear if this indicates an ongoing priming process or is the result of an immune response directed against myocytes. Such an inflammatory response was not likely to be a consequence of physical damage (e.g. needle injection or electroporation) or innate immunity towards bacterial plasmid DNA, as this was not seen in muscles injected with saline or blank vector.
We also found some central displacement of nuclei in the muscle fibers expressing CEA, and this did not appear to correlate with mononuclear cell infiltration. Centronuclear arrangement itself is a frequent nonspecific reaction of muscle fiber in many neuromuscular conditions that are, in general, not severe. 36 The mechanism of its occurrence in association with CEA expression is difficult to explain and requires further study. The ability of the CEA oncoprotein to alter the cellular architecture should be noted. 37, 38 In all treated groups, we did not see morphological features that indicate severe muscle damage, such as changes in muscle fiber size and structure. Also, in DNA-vaccinated mice kept for several months, we did not observe an apparent deterioration effect on their muscles compared to untreated mice.
Our study demonstrates the efficacy of i.m. gene transfer to deliver soluble B7.1/IgG 1 as a vaccine adjuvant. The method is robust, safe, and flexible. It permits simple and effective DNA vaccine design in cancer therapy. The fact that B7.1/IgG 1 was active as a circulating protein suggests that ongoing immune response against any tumor antigen (not just the antigen encoded by the plasmid) could be enhanced. This might provide a broader antitumor immunity than that generated by membrane-bound B7.1.
